PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
9.62%
Cash & equivalents growing 9.62% while AGEN's declined -30.55%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
9.62%
Below half of AGEN's -30.55%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.08%
Below half of AGEN's -46.31%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.18%
≥ 1.5x AGEN's -2.06%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.96%
Higher Long-Term Investments Growth compared to AGEN's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.38%
≥ 1.5x AGEN's -2.63%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
8.48%
Below half of AGEN's -18.27%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-5.53%
Less than half of AGEN's -17.50%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Less than half of AGEN's 9197.95%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
6569.50%
Below half of AGEN's -27.78%. Michael Burry suspects a big gap in pre-sales traction.
100.00%
Less than half of AGEN's -6.47%. David Dodd sees fewer expansions in other current obligations.
-5.06%
Less than half of AGEN's 0.04%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2126.46%
Above 1.5x AGEN's -8.14%. Michael Burry sees a much bigger deferred tax load building up.
No Data
No Data available this quarter, please select a different quarter.
-0.39%
Less than half of AGEN's -7.52%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-1.27%
Less than half of AGEN's -3.33%. David Dodd sees far fewer liability expansions relative to competitor.
3.57%
Less than half of AGEN's -94.68%. David Dodd sees fewer share issuances vs. competitor.
-2.57%
0.75-0.9x AGEN's -3.16%. Bill Ackman questions if competitor reinvests profits more robustly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.56%
Below half AGEN's -25.63%. Michael Burry sees potential underperformance in building shareholder capital.
8.48%
Below half AGEN's -18.27%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.96%
Higher Total Investments Growth compared to AGEN's zero value, indicating better performance.
-6.20%
Above 1.5x AGEN's -0.72%. Michael Burry sees a major jump. Investigate leverage rationale.
-10.07%
Less than half of AGEN's 7.56%. David Dodd sees better deleveraging or stronger cash buildup than competitor.